Related Experiment Video
Updated: Jun 27, 2026
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Hospitalized patients with acute decompensated heart failure: recognition, risk stratification, and treatment review
1University of California Irvine, Irvine, CA 92868, USA. anamin@uci.edu
Insights
Acute decompensated heart failure (ADHF) is a significant health issue. Early detection using B-type natriuretic peptide and risk stratification are key to improving outcomes and reducing costs.
Area of Science:
- Cardiology
- Internal Medicine
- Clinical Research
Background:
- Acute decompensated heart failure (ADHF) represents a substantial healthcare burden, accounting for 3% of US hospitalizations and $18.8 billion annually.
- Traditional diagnostic signs of ADHF may be absent or non-specific, necessitating more accurate detection methods.
- Identifying key mortality risk factors is crucial for effective patient management and resource allocation.
Purpose of the Study:
- To highlight the importance of early recognition, risk stratification, and evidence-based treatment for ADHF.
- To discuss the utility of serum B-type natriuretic peptide levels in diagnosing ADHF.
- To outline established risk factors and treatment guidelines for ADHF.
Main Methods:
- Utilized multivariate analyses to identify independent mortality risk factors in ADHF patients.
- Reviewed evidence-based treatment guidelines from major cardiology societies.
- Examined the role of B-type natriuretic peptide in ADHF diagnosis.
Main Results:
- Serum B-type natriuretic peptide levels offer rapid and accurate ADHF detection.
- Renal dysfunction, hypotension, advanced age, hyponatremia, and comorbidities are significant mortality risk factors.
- Validated algorithms exist for stratifying ADHF patient mortality risk.
- Intravenous diuretics and vasodilators are recommended initial therapies for volume overload; inotropes are reserved for low-output syndrome.
Conclusions:
- Early recognition and risk stratification are vital for managing ADHF, reducing morbidity, mortality, and healthcare costs.
- Serum B-type natriuretic peptide testing and validated risk algorithms aid in accurate diagnosis and prognosis.
- Adherence to evidence-based treatment guidelines, including diuretics and vasodilators, and careful patient monitoring are essential for optimal ADHF management.
- Patient education can play a role in reducing hospital readmissions.
Abstract:
Acute decompensated heart failure (ADHF) has emerged as a major healthcare problem. It causes approximately 3% of all hospitalizations in the United States, with the direct medical cost of these hospitalizations estimated at $18.8 billion per year. Early recognition, risk stratification, and evidence-based treatment are crucial in reducing the morbidity, mortality, and costs associated with this disorder. Classic signs and symptoms of ADHF, such as rales, dyspnea, and peripheral edema, may be absent at hospital presentation and, even when present, are not specific to this disorder. As a result, serum B-type natriuretic peptide level is now used to rapidly and accurately detect ADHF. Multivariate analyses have identified renal dysfunction, hypotension, advanced age, hyponatremia, and comorbidities as significant and independent mortality risk factors. Based on these factors, mortality risk can be stratified from very low to very high using published algorithms that have been validated in independent populations. Evidence-based guidelines for the treatment of ADHF are available from both the European Society of Cardiology and the Heart Failure Society of America. In general, an intravenous loop diuretic, either alone or in combination with a vasodilator, is recommended as initial therapy in patients with volume overload, depending on the patient's clinical status. Use of inotropic agents should be limited to the small subset of patients with low-output syndrome and significant hypotension. In any event, frequent monitoring of clinical response is essential, with subsequent therapy determined by this response. Finally, focused patient education during hospitalization may help reduce readmissions for ADHF.
Related Concept Videos
01:30Heart Failure V: Medical Management
01:30Heart Failure IV: Classification and Diagnostic Evaluation
01:30Heart Failure VII: Nursing Interventions
01:26Heart Failure III: Clinical Manifestations
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:22Heart Failure VI: Adjunct Therapies